ADIAL PHARMACEUTICALS, INC. (ADIL) Form S-3/A — Oct 20, 2026
Adial Pharmaceuticals filed an S-3/A registering up to 25,148,970 shares of common stock for resale by selling stockholders tied to its June 2026 acquisition of Azora Therapeutics, a $26.8 million PIPE, and the retirement of $5.5 million of Azora notes. The company will receive no proceeds from these resales. The registered shares dwarf Adial's 2,625,890 shares outstanding, creating an extreme dilution overhang. Resales are also blocked pending a stockholder vote that has been adjourned three times and is now set for October 26, 2026, awaiting Nasdaq's conditional approval of an Initial Listing Application for what Nasdaq deems a change of control.
Key figures
- Cash Position
- 28700000
- Offering Price
- 3.82
- Shares Offered
- 25148970
- Shares Outstanding
- 27337439
- Trigger date
- 2026-12-11
- Pipe warrant shares
- 9749345
- Merger common shares
- 437421
- Pipe net proceeds usd
- 24300000
- Adjourned meeting date
- 2026-10-26
- Azora notes retired usd
- 5500000
- Pipe gross proceeds usd
- 26800000
- Merger conversion shares
- 12930601
- Noteholder warrant shares
- 2031603
- Last sale price 2026 10 20
- 3.82
- Preferred cash settlement cost usd
- 51900000
- Shares outstanding before offering
- 2625890
- Nasdaq stockholders equity requirement usd
- 2500000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.